REACT Market

“REACT Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about REACT for Diabetic Kidney Disease (DKD) in the seven major markets. A detailed picture of the REACT for DKD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the REACT for DKD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REACT market forecast analysis for DKD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in DKD.

Drug Summary

REACT, is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes selected renal cells (SRC) prepared from a patient’s autologous renal cells. SRC are formulated into a product for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that can be repeated if necessary. Because REACT is a personalized treatment composed of cells prepared from a patient’s kidney, there is no need for treatment with immunosuppressive therapies, which are required during a patient’s lifetime when a patient receives a kidney transplant from another allogeneic donor.

The company is currently conducting a Phase III development program and multiple Phase II clinical trials for REACT in subjects with moderate to severe diabetic kidney disease. The company also recently completed a Phase I clinical trial for REACT in subjects with congenital anomalies of the kidney and urinary tract (CAKUT). REACT has been generally well tolerated by subjects with moderate to severe diabetic kidney disease in Phase I and II clinical testing to date. It has also been shown to preserve kidney function and limit kidney injury in subjects based on measurements of iohexol renal clearance and urinary albumin-to-creatinine ratio (UACR).

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the REACT description, mechanism of action, dosage and administration, research and development activities in Diabetic Kidney Disease (DKD).
• Elaborated details on REACT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the REACT research and development activities in DKD across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around REACT.
• The report contains forecasted sales of REACT for DKD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DKD.
• The report also features the SWOT analysis with analyst views for REACT in DKD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REACT Analytical Perspective by DelveInsight

• In-depth REACT Market Assessment

This report provides a detailed market assessment of REACT for Diabetic Kidney Disease (DKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• REACT Clinical Assessment

The report provides the clinical trials information of REACT for Diabetic Kidney Disease (DKD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Diabetic Kidney Disease (DKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REACT dominance.
• Other emerging products for DKD are expected to give tough market competition to REACT and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REACT in DKD.
• Our in-depth analysis of the forecasted sales data of REACT from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REACT in DKD. 

Key Questions

• What is the product type, route of administration and mechanism of action of REACT?
• What is the clinical trial status of the study related to REACT in Diabetic Kidney Disease (DKD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REACT development?
• What are the key designations that have been granted to REACT for DKD?
• What is the forecasted market scenario of REACT for DKD?
• What are the forecasted sales of REACT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to REACT for DKD?
• Which are the late-stage emerging therapies under development for the treatment of DKD?